공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세포 신호전달 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년)

Cell Signaling Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2021년 03월 상품 코드 707235
페이지 정보 영문
가격
US $ 4,250 ₩ 4,788,000 PDF (Single User License)
US $ 4,750 ₩ 5,352,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 6,760,000 PDF (Site License)
US $ 7,500 ₩ 8,451,000 PDF (Corporate License)


세포 신호전달 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년) Cell Signaling Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
발행일 : 2021년 03월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 세포 신호전달(Cell Signaling) 시장에 대해 조사했으며, 시장 개요, 신호·제품·기술·전달 경로·용도·지역별 시장 규모 추정과 예측, 시장 동향, 시장 규모 추정과 예측, 성장 촉진요인·저해요인 및 시장 기회 분석, 경쟁 상황, 주요 기업 개요 등의 정보를 전해드립니다.

목차

제1장 서론

  • 시장 정의

제2장 조사 방법

제3장 주요 요약

제4장 주요 영향요인

제5장 시장 개요

  • 현재 시장 시나리오
  • Porter's Five Forces 분석
    • 구매자의 협상력
    • 공급 기업의 협상력
    • 신규 참여업체의 위협
    • 대체품의 위협
    • 경쟁 기업간 경쟁 관계

제6장 시장 역학

  • 성장 촉진요인
    • 만성질환 발생률 상승
    • 세포 연구를 위한 자금 조달 증가
    • 세포 연구 기기의 기술적 진보
  • 성장 저해요인
    • 세포 신호전달 시스템의 고비용
    • 배아줄기세포 신호전달 연구와 관련된 윤리적 문제
  • 시장 기회
    • 세포 생물학 연구에서 미세유체의 등장
  • 과제
    • 항체 및 시약 개발의 복잡성

제7장 시장 분석 : 부문별

  • 신호별
    • 내분비 신호전달
    • 측분비 신호전달
    • 자기분비 신호전달
    • 접촉분비 신호전달
    • 기타
  • 제품별
    • 소모품
    • 장비
  • 기술별
    • 현미경 검사
    • 유세포 분석
    • 질량 분석
    • 웨스턴 블로팅
    • ELISA
    • 면역조직화학
    • 기타
  • 전달 경로별
    • AKT 신호전달 경로
    • AMPK 신호전달 경로
    • ErbB/HER 신호전달 경로
    • Hedgehog 신호전달 경로
    • JAK/STAT 신호전달 경로
    • Notch 신호전달 경로
    • NF-KB 신호전달 경로
    • 기타
  • 용도별
    • 연구
    • 의료
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동 및 아프리카
    • 남미

제8장 기업 개요와 경쟁 상황

  • Beckman Coulter Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • Bio-Techne Corporation
  • Cell Signaling Technology Inc.
  • Merck KGaA
  • PerkinElmer Inc.
  • Promega Corporation
  • Qiagen NV
  • Thermo Fisher Scientific Inc.

제9장 시장의 향후 전망

KSM 18.10.05

The cell signaling market is expected to register a CAGR of nearly 6.2% during the forecast period, with a revenue of approximately USD 3,455 million in 2020, and it is expected to reach USD 4,945 million by 2026.

The COVID-19 is likely to have a profound impact on the market studied. A new study published in the journal News Medical, "SARS-CoV-2 spike protein triggers cell signaling pathways in lung vascular cells" in October 2020 stated that vascular cells in the lung tissue begin to secrete signaling growth factors when exposed to just the spike protein of severe acute respiratory syndrome coronavirus without the rest of the viral components. As this signaling mechanism is potentially linked to worse outcomes in this situation, these findings could indicate new targets for the development of therapeutic agents. Thus, the high utility of cell signaling models for research about COVID-19 and respiratory diseases is expected to offer significant growth opportunities to the market.

The major factors for the growth of the cell signaling market include the rising incidence of chronic diseases, increased funding for cell-based research, and technological advancements in cell-based research instruments. There is rising funding for cell-based research across the world.

For instance, according to the data available on the portal for the National Institutes of Health (NIH), an estimated USD 1,626 million was granted for stem cell research in the fiscal year 2019. In contrast, the actual fund grants for stem cell research in the fiscal year 2018, amounted to USD 1,748 million.

Similar increments in funding grants were observed for research in the areas of embryonic stem cell and induced pluripotent stem cell. Similar positive trends in the increment of fund grants have been observed in the European Union for cell-based research. Consequently, the increasing participation of government for the development of cell-based research, in the form of incremental funding, is expected to drive the growth of the market studied. Other factors contributing to the growth of the market studied include the increasing incidence of chronic diseases and technological advancements in cell-based research instruments.

However, high cost of cell signaling systems and ethical issues related to embryonic stem cell signaling research is likely to hindered the market growth.

Key Market Trends

AKT Signaling Pathway is Expected to Register Good Growth Over the Forecast Period

The AKT signaling pathway, also known as the survival pathway, is responsible for the increased proliferation, loss of apoptosis signaling, and cell growth. The AKT signaling pathway is the most commonly dysregulated pathway in the most prevalent forms of cancer. A number of drugs have been designed, based on the rationale that inhibition of AKT pathway could help in achieving therapeutic results. A number of drugs based on AKT signaling are currently in various stages of clinical trials.

In the treatment of the advanced-stage COVID-19 patients, Akt found as a potential therapeutic target. Its inhibition will potentially suppress the cytokine storm, fibroproliferation, pathological inflammation, and platelet activation associated with COVID-19. It also promotes resolution and prevents scarring in injured lungs. As per the study published "Akt a viable option to treat advanced-stage COVID-19 patients" in 2020, reported that pharmacological inhibition of Akt has also been reported to inhibit angiotensin-converting enzyme 2 (ACE2) expression, a receptor for the virus entry into the lung cells, targeting Akt for COVID-19 looks a viable option. Thus, the segment is likely to have positive impact on the segment studied.

AKT inhibitors can be classified into four categories. The first category consists of competitive inhibitors of the ATP binding site on the kinase domain. The second category is allosteric inhibitors of the AKT kinase domain. Other similar categories of the drug exist, which are based on the regulation of AKT pathway. Overall, the market for the AKT signaling pathway has the largest share, due to the comprehensive list of pipeline drugs, which are based on the regulation of AKT signaling.

Over the forecast period, this market is expected to increase, as commercial diagnostic tests are expected to emerge, based on down-regulation of the AKT pathway. This is likely to be employed as a biomarker in cancer diagnosis.

North America is Expected to Dominate the Market Over the Forecast Period

North America is found to hold a major share of the cell signaling market and is expected to show a similar trend over the forecast period, without significant fluctuations. The cell signaling market is expected to witness numerous growth opportunities during the pandemic, with cell signaling pathways being utilized as experimental virology platforms to study the immune responses and infectivity of SARS-CoV-2. Most of the major players has been involved in R&D activities regarding cell signaling pathways. The mortality in most of the COVID-19 patients is due to the presence of a cytokine storm, which is induced by the virus. The excessive production of these proinflammatory cytokines leads to acute respiratory distress syndrome aggravation and widespread tissue damage, which results in multi-organ failure and death. Thus, targeting cell signaling pathways such as cytokines during the management of COVID-19 may lead to the reduction of the mortality rate and improved outcomes. This is likely to have a positive impact on the market studied.

In the United States, for the fiscal year 2018, USD 520 million was granted by the federal government, for the National Cancer Institute (NCI) budget, for breast cancer research, USD 212 million for colorectal cancer research, USD 241 million for leukemia. Additionally, the estimates available on the National Institute of Health portal for stem cell-based research indicate a cumulative funding budget of more than USD 3 billion, for research in various fields of stem cell applications. The need for cell signaling in cancer research plays a vital role in the progressive growth of the cell signaling market in the United States. The growing funding in cancer research and stem cell research are directly causing an increase in the cell signaling research area, particularly in the United States. The increasing trend of increment in research funding is expected to lead to the growth of the market studied in the United States.

Competitive Landscape

The market studied is a moderately consolidated market owing to the presence of the small and large market players. Some of the market players are Beckman Coulter Inc. (Danaher), Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Cell Signaling Technology Inc., Merck KGaA, PerkinElmer Inc., Promega Corporation, Qiagen N.V., and Thermo Fischer Scientific Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Burden of Chronic Diseases
    • 4.2.2 Increased Funding for Cell-based Research
    • 4.2.3 Technological Advancements in Cell-based Research Instruments
  • 4.3 Market Restraints
    • 4.3.1 High cost of Cell Signaling Systems
    • 4.3.2 Ethical Issues Related to Embryonic Stem Cell Signaling Research
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Signaling Type
    • 5.1.1 Endocrine Signaling
    • 5.1.2 Paracrine Signaling
    • 5.1.3 Autocrine Signaling
    • 5.1.4 Synaptic Signaling
    • 5.1.5 Other Signaling Types
  • 5.2 By Product
    • 5.2.1 Instruments
    • 5.2.2 Consumables
  • 5.3 By Technology
    • 5.3.1 Flow Cytometry
    • 5.3.2 Mass Spectrometry
    • 5.3.3 Western Blotting
    • 5.3.4 ELISA
    • 5.3.5 Other Technologies
  • 5.4 By Pathway
    • 5.4.1 AKT Signalling Pathway
    • 5.4.2 AMPK Signalling Pathway
    • 5.4.3 ErbB/HER Signaling Pathway
    • 5.4.4 Other Signaling Pathways
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Becton, Dickinson and Company
    • 6.1.2 Bio-Rad Laboratories Inc.
    • 6.1.3 Bio-Techne Corporation
    • 6.1.4 Cell Signaling Technology Inc.
    • 6.1.5 Danaher Corporation (Beckman Coulter Inc.)
    • 6.1.6 Merck KGaA
    • 6.1.7 PerkinElmer Inc.
    • 6.1.8 Promega Corporation
    • 6.1.9 Qiagen NV
    • 6.1.10 Thermo Fischer Scientific Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q